JP2002523400A5 - - Google Patents

Download PDF

Info

Publication number
JP2002523400A5
JP2002523400A5 JP2000566249A JP2000566249A JP2002523400A5 JP 2002523400 A5 JP2002523400 A5 JP 2002523400A5 JP 2000566249 A JP2000566249 A JP 2000566249A JP 2000566249 A JP2000566249 A JP 2000566249A JP 2002523400 A5 JP2002523400 A5 JP 2002523400A5
Authority
JP
Japan
Prior art keywords
optionally substituted
hydrogen atom
pharmaceutically acceptable
alkyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000566249A
Other languages
English (en)
Japanese (ja)
Other versions
JP4445133B2 (ja
JP2002523400A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP1999/004443 external-priority patent/WO2000010975A1/en
Publication of JP2002523400A publication Critical patent/JP2002523400A/ja
Publication of JP2002523400A5 publication Critical patent/JP2002523400A5/ja
Application granted granted Critical
Publication of JP4445133B2 publication Critical patent/JP4445133B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000566249A 1998-08-20 1999-08-18 オキシインドール誘導体 Expired - Fee Related JP4445133B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP10-234643 1998-08-20
JP23464398 1998-08-20
PCT/JP1999/004443 WO2000010975A1 (en) 1998-08-20 1999-08-18 Oxindole derivatives as growth hormone releasers

Publications (3)

Publication Number Publication Date
JP2002523400A JP2002523400A (ja) 2002-07-30
JP2002523400A5 true JP2002523400A5 (enExample) 2006-07-27
JP4445133B2 JP4445133B2 (ja) 2010-04-07

Family

ID=16974248

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000566249A Expired - Fee Related JP4445133B2 (ja) 1998-08-20 1999-08-18 オキシインドール誘導体

Country Status (11)

Country Link
US (1) US6576656B1 (enExample)
EP (1) EP1105376B1 (enExample)
JP (1) JP4445133B2 (enExample)
KR (1) KR100680085B1 (enExample)
CN (1) CN1161333C (enExample)
AT (1) ATE288895T1 (enExample)
AU (1) AU5301199A (enExample)
CA (1) CA2340701C (enExample)
DE (1) DE69923692T2 (enExample)
ES (1) ES2237135T3 (enExample)
WO (1) WO2000010975A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085695A1 (en) 2000-05-11 2001-11-15 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
US6939887B2 (en) * 2001-01-30 2005-09-06 Sumitomo Pharmaceuticals Co., Ltd. Benzimidazolidinone derivatives
AU2002357692A1 (en) 2001-11-09 2003-05-26 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
SE0104341D0 (sv) * 2001-12-20 2001-12-20 Astrazeneca Ab New use
US7342022B2 (en) 2001-12-21 2008-03-11 Astrazeneca Ab Compounds in the treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3
TW200301123A (en) * 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
MXPA05002734A (es) * 2002-10-24 2005-05-23 Pfizer Prod Inc Derivados de acilo de 5- (2-(4 -(1, 2-bencisotiazol -3-il) -1-piperazinil) etil)- 6-cloro -1, 3-dihidro -2h- indol -2-ona que presentan actividad neuroleptica.
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US6912165B2 (en) * 2003-08-22 2005-06-28 International Business Machines Corporation Method for transparent updates of output driver impedance
JPWO2005035498A1 (ja) * 2003-10-08 2006-12-21 住友製薬株式会社 含窒素二環性化合物の摂食調節剤としての用途
AU2005277389A1 (en) 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
JPWO2007032371A1 (ja) 2005-09-14 2009-03-19 大日本住友製薬株式会社 摂食調節剤としてのオキシインドール誘導体
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
US9371297B2 (en) 2007-02-09 2016-06-21 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
FR2920023B1 (fr) * 2007-08-16 2013-02-08 Sanofi Aventis Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
US20110086834A1 (en) * 2008-06-26 2011-04-14 Amgen Inc. Alkynyl alcohols as kinase inhibitors
FR2941947B1 (fr) * 2009-02-12 2011-03-25 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique
FR2941946B1 (fr) * 2009-02-12 2011-03-25 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
EP2246326A1 (de) * 2009-05-02 2010-11-03 Bayer CropScience AG Verfahren zur Herstellung von Oxindolen und ortho-substituierten Anilinen und ihre Verwendung als Zwischenprodukte für Synthesen
AU2012328476B2 (en) 2011-10-28 2017-03-30 Vanderbilt University Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1
WO2013071201A1 (en) 2011-11-11 2013-05-16 Vanderbilt University Substituted benzylspiroindolin-2-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1
US9029563B2 (en) 2012-01-06 2015-05-12 Vanderbilt University Substituted 1-benzylindolin-2-one analogs as positive allosteric modulators of muscarinic acetylcholine M1 receptors
US8697888B2 (en) * 2012-01-06 2014-04-15 Vanderbilt University Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors
WO2013106795A1 (en) 2012-01-12 2013-07-18 Vanderbilt University Substituted 4-(1h~pyrazol-4.yl)benzyl analogues as positive allosteric modulators of machr m1 receptors
CN104853778A (zh) 2012-10-24 2015-08-19 第一三共株式会社 用于肌萎缩性侧索硬化的治疗剂
CN119409618B (zh) * 2024-09-30 2025-10-10 厦门大学 一种吲哚衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB125671A (en) 1917-07-03 1919-05-01 James Rossiter Hoyle Improvements in or relating to Armour Piercing Projectiles.
US3441570A (en) * 1966-01-20 1969-04-29 Parke Davis & Co 3-tertiary aminoalkylamino-3-phenyl oxindole compounds
US3891644A (en) * 1971-01-11 1975-06-24 Wyeth John & Brother Ltd 10,10-Disubstituted-2,3,4,10-tetrahydro-and 1,2,3,4,10a-hexahydropyrimidol {8 1,2-a{9 indole derivatives
GB1450137A (en) 1973-12-20 1976-09-22 Wyeth John & Brother Ltd Indole derivatives
US5283241A (en) 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone

Similar Documents

Publication Publication Date Title
JP2002523400A5 (enExample)
JP2005515255A5 (enExample)
JP2005536475A5 (enExample)
JP2001526218A5 (enExample)
JP2005531516A5 (enExample)
JP2011515398A5 (enExample)
JP2004504404A5 (enExample)
JP2006501201A5 (enExample)
JP2004517099A5 (enExample)
JP2003503449A5 (enExample)
JP2005504042A5 (enExample)
JP2005524628A5 (enExample)
ES2314418T3 (es) Derivados de amidas del acido 4-bromo-5-(2-clorobenzoilamino)-1h-pirazol-3-carboxicilico y compuestos relacionados como antagonistas del receptor b1 de bradiquinina para el tratamiento de enfermedades inflamatorias.
JP2005531488A5 (enExample)
JP2009538897A5 (enExample)
JP2010500376A5 (enExample)
JP2007520440A5 (enExample)
JP2005527542A5 (enExample)
CA2539349A1 (en) 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
JP2014521595A5 (enExample)
JP2005526696A5 (enExample)
JP2004529145A5 (enExample)
EA200501703A1 (ru) Применение производных азетидинкарбоксамида в терапии
JP2003507380A5 (enExample)
RU2007116987A (ru) Новые соединения